Cargando…
Hepatitis B Virus Immunopathology, Model Systems, and Current Therapies
Most people develop acute hepatitis B virus (HBV)-related hepatitis that is controlled by both humoral and cellular immune responses following acute infection. However, a number of individuals in HBV-endemic areas fail to resolve the infection and consequently become chronic carriers. While a vaccin...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5390110/ https://www.ncbi.nlm.nih.gov/pubmed/28450868 http://dx.doi.org/10.3389/fimmu.2017.00436 |
_version_ | 1782521390356758528 |
---|---|
author | Sandhu, Praneet Haque, Mohammad Humphries-Bickley, Tessa Ravi, Swetha Song, Jianxun |
author_facet | Sandhu, Praneet Haque, Mohammad Humphries-Bickley, Tessa Ravi, Swetha Song, Jianxun |
author_sort | Sandhu, Praneet |
collection | PubMed |
description | Most people develop acute hepatitis B virus (HBV)-related hepatitis that is controlled by both humoral and cellular immune responses following acute infection. However, a number of individuals in HBV-endemic areas fail to resolve the infection and consequently become chronic carriers. While a vaccine is available and new antiviral drugs are being developed, elimination of persistently infected cells is still a major issue. Standard treatment in HBV infection includes IFN-α, nucleoside, or nucleotide analogs, which has direct antiviral activity and immune modulatory capacities. However, immunological control of the virus is often not durable. A robust T-cell response is associated with control of HBV infection and liver damage; however, HBV-specific T cells are deleted, dysfunctional, or become exhausted in chronic hepatitis patients. As a result, efforts to restore virus-specific T-cell immunity in chronic HBV patients using antiviral therapy, immunomodulatory cytokines, or therapeutic vaccination have had little success. Adoptive cell transfer of T cells with specificity for HBV antigen(+) cells represents an approach aiming to ultimately eliminate residual hepatocytes carrying HBV covalently closed circular DNA (cccDNA). Here, we discuss recent findings describing HBV immunopathology, model systems, and current therapies. |
format | Online Article Text |
id | pubmed-5390110 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-53901102017-04-27 Hepatitis B Virus Immunopathology, Model Systems, and Current Therapies Sandhu, Praneet Haque, Mohammad Humphries-Bickley, Tessa Ravi, Swetha Song, Jianxun Front Immunol Immunology Most people develop acute hepatitis B virus (HBV)-related hepatitis that is controlled by both humoral and cellular immune responses following acute infection. However, a number of individuals in HBV-endemic areas fail to resolve the infection and consequently become chronic carriers. While a vaccine is available and new antiviral drugs are being developed, elimination of persistently infected cells is still a major issue. Standard treatment in HBV infection includes IFN-α, nucleoside, or nucleotide analogs, which has direct antiviral activity and immune modulatory capacities. However, immunological control of the virus is often not durable. A robust T-cell response is associated with control of HBV infection and liver damage; however, HBV-specific T cells are deleted, dysfunctional, or become exhausted in chronic hepatitis patients. As a result, efforts to restore virus-specific T-cell immunity in chronic HBV patients using antiviral therapy, immunomodulatory cytokines, or therapeutic vaccination have had little success. Adoptive cell transfer of T cells with specificity for HBV antigen(+) cells represents an approach aiming to ultimately eliminate residual hepatocytes carrying HBV covalently closed circular DNA (cccDNA). Here, we discuss recent findings describing HBV immunopathology, model systems, and current therapies. Frontiers Media S.A. 2017-04-13 /pmc/articles/PMC5390110/ /pubmed/28450868 http://dx.doi.org/10.3389/fimmu.2017.00436 Text en Copyright © 2017 Sandhu, Haque, Humphries-Bickley, Ravi and Song. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Sandhu, Praneet Haque, Mohammad Humphries-Bickley, Tessa Ravi, Swetha Song, Jianxun Hepatitis B Virus Immunopathology, Model Systems, and Current Therapies |
title | Hepatitis B Virus Immunopathology, Model Systems, and Current Therapies |
title_full | Hepatitis B Virus Immunopathology, Model Systems, and Current Therapies |
title_fullStr | Hepatitis B Virus Immunopathology, Model Systems, and Current Therapies |
title_full_unstemmed | Hepatitis B Virus Immunopathology, Model Systems, and Current Therapies |
title_short | Hepatitis B Virus Immunopathology, Model Systems, and Current Therapies |
title_sort | hepatitis b virus immunopathology, model systems, and current therapies |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5390110/ https://www.ncbi.nlm.nih.gov/pubmed/28450868 http://dx.doi.org/10.3389/fimmu.2017.00436 |
work_keys_str_mv | AT sandhupraneet hepatitisbvirusimmunopathologymodelsystemsandcurrenttherapies AT haquemohammad hepatitisbvirusimmunopathologymodelsystemsandcurrenttherapies AT humphriesbickleytessa hepatitisbvirusimmunopathologymodelsystemsandcurrenttherapies AT raviswetha hepatitisbvirusimmunopathologymodelsystemsandcurrenttherapies AT songjianxun hepatitisbvirusimmunopathologymodelsystemsandcurrenttherapies |